Eligible commercially insured patients who are prescribed HEMLIBRA for an FDA-approved use can receive up to $15,000 per calendar year for drug costs. For more information, see full program Terms and Conditions.
Effective May 11, 2023, the HEMLIBRA Co-pay Program has two program updates:
Eligible claims submitted to the HEMLIBRA Co-pay Program with a date of service on or after May 11, 2023 will be processed and patients may pay as little as $0 co-pay.
For more information, please call the Help Desk at (844) 436-2672.
The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
Eligible commercially insured patients who are prescribed HEMLIBRA for an FDA-approved use can receive up to $15,000 per calendar year for drug costs. For more information, see full program Terms and Conditions.
At any time, click this to change word size.